Methods for treating cancer with activating antigen carriers
AssigneeStemcell Technologies Canada Inc.
InventorOLIVER ROSEN
Life of this patent
Estimating the term…
Abstract
The present application provides activating antigen carriers (AACs) for treating HPV-associated cancers. AACs are derived from anucleate cells in which at least one antigen and an adjuvant have been delivered intracellularly. In some embodiments, the AAC is administered in combination with a checkpoint inhibitor such as a CTLA4 antagonist and/or a PD-1/PD-L1 agonist.
Claims20
A method for treating a cancer in an individual, the method comprising administering an effective amount of a composition comprising activating antigen carriers (AACs) to the individual wherein the effective amount is about 0.1×108 AACs/kg to about 1×109 AACs/kg,
- wherein the AACs are anucleate cells or anucleate cell-derived vesicles and comprise intracellularly at least one exogenous antigen and an adjuvant to enhance an immune response to the antigen as compared to the antigen alone,
- wherein the at least one antigen and the adjuvant were intracellularly delivered to the AACs by passing a cell suspension comprising a population of input anucleate cells through a cell-deforming constriction, thereby causing perturbations of the input anucleate cells, and wherein the at least one antigen and the adjuvant enter the perturbed input anucleate cells through the perturbations when contacted with the perturbed input anucleate cells to generate the AACs comprising the at least one antigen and the adjuvant, and
- wherein the effective amount of the composition comprising AACs decreases a tumor volume compared to a composition not comprising AACs.
Dependencies are inferred from the claim text.